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Abstract
Ultrasound (US) is not only an important diagnostic tool for the evaluation of the pancreas, but is also a fundamental
imaging technique to guide percutaneous interventions for several pancreatic diseases (fluid aspiration and drainage;
invasive diagnosis by means fine-needle aspiration and core-needle biopsy; tumour ablation by radiofrequency,
microwaves, irreversible electroporation, cryoablation, and high-intensity focused US). Technical improvements,
such as contrast media and fusion imaging, have recently increased precision and safety and reduced procedure-
related complications. New treatment US techniques for the ablation of pancreatic tumours, such as contrast-
enhanced US and multimodality fusion imaging, have been recently developed and have elicited a growing
interest worldwide. The purpose of this article was to review the most up-to-date role of US in percutaneous
procedures for pancreatic diseases.
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Key points
 Ultrasound is a fundamental imaging guidance in
percutaneous intervention for pancreatic diseases.
 Technical improvements have increased precision
and safety of percutaneous ultrasound-guided
interventions.
 Percutaneous ultrasound-guided ablation of pancreatic
tumours has been recently developed.
Background
Ultrasound (US) has a central role in the evaluation of
pancreatic diseases, especially in European and Asiatic
Countries. Over the last decades, there have been con-
tinuous improvements in both US technology and spe-
cialists’ expertise, which expanded the capabilities of US
during percutaneous intervention in several pancreatic
diseases. Transabdominal US is faster and cheaper than
computed tomography (CT), magnetic resonance
imaging (MRI), and endoscopic US (EUS). However, US
is strongly dependent on operator expertise, in particular
when used as a guidance for interventional procedures
for pancreatic diseases. In this case, transabdominal US
is particularly helpful for minimally invasive procedures
with percutaneous approach, as it guarantees a real-time
imaging that allows to precisely evaluate each step of the
procedure.
The most commonly performed percutaneous US-
guided procedures on the pancreas are fluid drainage,
especially after surgery or acute pancreatitis, and inva-
sive diagnostic of pancreatic masses. Recently, several
percutaneous ablative treatments, which have a proven
therapeutic role for hepatic and renal malignancies, have
been applied to pancreatic malignancies. Differently
from fluoroscopy and CT, when percutaneous interven-
tion is performed under US guidance, it is possible to
compress the patient’s abdominal wall with the US probe
in order to displace intraperitoneal organs and bowels,
thus reducing both the length of the path from the skin
to the target and the superimposition of air, which are
essential to minimise complications.
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The purpose of this article was to review the most
up-to-date role of US in percutaneous procedures for
pancreatic diseases, also focusing on new techniques and
applications.
Fluid aspiration and drainage
Aspiration and drainage of peripancreatic fluid collec-
tions is frequently performed percutaneously under US
guidance. Fluid collections are common after pancreatic
surgery. They may represent different pathological en-
tities such as exudate, bile, blood, or infection. Surgical
drainage tubes are usually present when fluid collections
are seen at post-operative imaging, making easier their
characterisation; when drainage tubes are absent, percu-
taneous US-guided diagnostic aspiration should be per-
formed to guide further management. Generally
speaking, almost every symptomatic post-operative fluid
collection should undergo percutaneous drainage; percu-
taneous drainage is mandatory when signs of superim-
posed infection are present. According to the latest
recommendations proposed by the International Study
Group for Pancreatic Fistula, percutaneous drainage of
post-operative collections related to a pancreatic fistula
should be performed only in patients with a grade B
post-operative pancreatic fistula [1]. Peri- or intrapan-
creatic fluid collections are typically associated with
acute pancreatitis and almost always resolve without any
treatment [2].
According to the revised Atlanta classification [3], the
severity or stage of acute pancreatitis drive the type of
treatment that the patient needs. About 25% pseudocysts
associated with interstitial acute pancreatitis become
symptomatic or infected and necessitate drainage [4].
Percutaneous US-guided drainage has proved to be an
effective alternative to surgery in patients with acute
necrotising pancreatitis; nevertheless, the approaches to
sterile and infected necrotic collections are different.
Necrotic collections without signs of infection at CT
should be considered as sterile until otherwise proven,
and percutaneous drainage should be avoided, as this
procedure has the potential of infection by means of
colonisation of the drainage catheter [4]. Nevertheless,
patients without radiologic evidence of infection, who do
not do well clinically or present clinical instability, may
benefit from US-guided aspiration to rule out infected
necrosis. When infected necrosis is present, large-sized,
or multiple, percutaneous drainage catheters should be
placed into the collection as a bridge or as an alternative
to surgical debridement.
Invasive diagnosis of pancreatic lesions
Although all imaging techniques can be used to manage
pancreatic fine-needle aspiration (FNA) and core-needle
biopsy (CNB) of pancreatic lesions, US is certainly one
of the most used. The endoscopic approach has been in-
creasingly used worldwide for tissue sampling in pancre-
atic diseases. However, EUS guidance is not available in
all centres, it is expensive and time-consuming, and re-
quires at least deep sedation of the patient.
The most recent guidelines of the European Feder-
ation of Society for Ultrasound in Medicine and Biology
(EFSUMB) on diagnostic US-guided interventional pro-
cedures [5] provided the following indications to inva-
sive diagnosis of pancreatic lesions: characterisation of a
solid unresectable pancreatic mass; differential diagnosis
between neoplasm and focal inflammatory conditions;
suspicion of an uncommon entity (i.e. metastases,
lymphoma), even if resectable, which could be treated
non-operatively; Ki-67 quantification for the prognosis
of neuroendocrine neoplasms; cystic lesions that are un-
defined or suspicious for malignancy after MR imaging
evaluation.
The same guidelines recommended that unresectable,
locally advanced pancreatic masses should be evaluated
for percutaneous US-guided biopsy first (Fig. 1), and if
percutaneous approach is not feasible, then EUS should
be considered; moreover, cystic lesions that require patho-
logical diagnosis should be always sampled through an
endoscopic approach. Contraindications to the procedure
include uncooperative patients and non-correctable bleed-
ing disorders.
Fine-needle aspiration needles range from 23G to 20G
in calibre [6]. Menghini-modified needles work with an
aspiration modality, while Chiba needles collect cells
through capillarity; several studies have reported the su-
periority of aspiration needles, in particular for lesions
with a low cellular density, as pancreatic ductal adenocar-
cinoma [7, 8]. Previous studies reported high sensitivity
and accuracy values of percutaneous US-FNA for the
diagnosis of pancreatic masses, even above 98% [9–11],
which are comparable to those of EUS-FNA [12]. More-
over, percutaneous FNA have similar and relatively low
complication rate compared with EUS-FNA, ranging
between 0 and 5%, and almost always limited to
post-procedural pain or mild abdominal effusion [10–14].
When a complete tissue analysis is needed for a correct
histological diagnosis and for further pathological ana-
lyses, as Ki-67 quantification in neuroendocrine neo-
plasms, FNA is not adequate, as it only provides a
cytological specimen with few histologic structures. More-
over, when FNA is performed without the immediate
evaluation of the specimen by a cytopathologist, the pro-
cedure must be repeated in a different session if the sam-
ple results inadequate for a final pathological diagnosis.
Core-needle biopsy (CNB) overcomes all these limitations,
because it provides preserved tissue structures for histo-
logic analysis and molecular characterisation. Coaxial cut-
ting needles are commonly used for CNB. No significant
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differences in complication rates have been reported be-
tween different calibres of the CNB needle, which nor-
mally ranges between 14 to 20G [6, 15]. Several studies
have reported very high sensitivity, specificity and accur-
acy values for CNB of pancreatic masses, with a diagnostic
rate that ranges between 92 and 96% [6]. Percutaneous
CNB has a higher risk of complications [6] compared with
US-FNA [10]. Therefore, percutaneous US-FNA, espe-
cially when performed in the presence of an experienced
cytopathologist, has sensitivity and accuracy values com-
parable to those of EUS-FNA and US-CNB, but it is
cheaper and with less complications.
Tumour ablation
Radical resection is the only treatment capable of improv-
ing long-term survival in patients with pancreatic cancer.
Surgical resection is possible only in 20–30% of patients
with pancreatic cancer and the 5-year survival rate is still
very low, even in combination with chemotherapy and
radiotherapy [16]. Tumour ablation was first proposed
under intraoperative US to debulk tumours that were
found to be unresectable during surgery, basing on previ-
ous effective experiences in other organs as the liver or
the kidney [17]. Afterwards, given the efficacy in terms of
mass shrinkage, pain relief, CA 19.9 reduction, and sur-
vival, this procedure has been introduced as a part of the
multidisciplinary approach to patients with pancreatic
cancer in high-volume centres [18, 19]. As a consequence,
there was the need for minimally invasive (i.e. laparo-
scopic, percutaneous, and endoscopic) approaches (Fig. 2)
to avoid unnecessary laparotomies.
There are many ablative techniques for pancreatic cancer,
which can be divided in three groups: invasive, thermal
techniques, such as radiofrequency ablation (RFA), micro-
wave ablation (MWA), laser ablation, and cryoablation;
invasive, non-thermal techniques, such as ethanol injection
and irreversible electroporation (IRE); and non-invasive ab-
lative techniques, as high-intensity focused US (HIFU).
Among these techniques, RFA and IRE are the most used
for the ablation of pancreatic cancer; HIFU is an emerging
alternative.
Radiofrequency ablation induces coagulative necrosis
within the tumour mass through the production of high
temperatures, induced by the application of high-
frequency alternating current. While EUS is safer for le-
sions in the pancreatic head, the percutaneous approach
can be adopted for lesions located in the body of the pan-
creas [20]. The necrotic area produced by RFA depends
on the type of the needle-electrode. Moreover, technical
parameters, as power, influence the temperature and the
volume of necrosis. In the pancreas, the use of very high
temperature (above 100 °C) is related to a high risk of
complications without significant advantages, so several
studies have shown that a temperature of about 90 °C is
sufficient for a successful procedure, with lower risk of
complications [17, 21, 22]. Previous studies reported that
carbohydrate antigen (CA) 19.9 blood levels are reduced
after RFA of unresectable pancreatic cancer, thus indir-
ectly suggesting effective cytolysis of the tumour after ab-
lation [23]. It has been proven that RFA can provide a
reduction in back pain and analgesia requirement in inop-
erable patients [24]. Overall survival is longer in patients
treated with RFA instead of classical supportive care, espe-
cially when combined with chemotherapy, reaching up to
33months in unresectable pancreatic cancer [25, 26].
Despite the successful results, there are still few stud-
ies regarding percutaneous RFA of pancreatic lesions.
However, all authors agreed on the safety and effective-
ness of the procedure, not only for ductal adenocarcin-
oma [25] but also in neuroendocrine tumours [27, 28]
Fig. 1 Ultrasound-guided pancreatic lesion biopsy. The path of the needle can be precisely visualised during the planning phase (dotted line). The
tip of the needle can be exactly visualised during its insertion and stopped when in the target lesion (hyperechoic spot)
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and pancreatic metastases [29]. Owing to the above
mentioned results, US-guided RFA has been introduced
in the multidisciplinary approach to pancreatic cancer in
high-volume centres. Nevertheless, randomised clinical
trials on larger samples are needed in the future to valid-
ate this procedure.
Microwave ablation is based on tissue heating by
mechanical agitation of water molecules induced by mi-
crowaves, which ultimately causes coagulative necrosis
[30]. Microwaves can spread throughout tissues inde-
pendently from their electric impedance: this allows to
produce faster and larger ablation areas than RFA, thus
requiring less applications to obtain complete tumour
necrosis [30]. Although literature reports on percutan-
eous US-guided MWA of pancreatic lesions are few, this
technique appears to be safe and promising for the treat-
ment of unresectable pancreatic tumours. Carrafiello et
al. [31] reported that this procedure was feasible in all
patients of their series, with only one procedure-related
complication. Ierardi et al. [32] reported improvement in
quality of life after US-guided percutaneous MWA in
five patients with pancreatic cancer.
Irreversible electroporation is the newest and most prom-
ising invasive technique for pancreatic cancer ablation. IRE
is based on the application of short high-voltage electric
pulses, in order to produce multiple micropores on cell
membranes causing an irreversible permeabilisation, which
leads to disruption of cellular homeostasis, activating apop-
totic pathways in tumour cells [33]. The main advantage of
IRE compared with other ablative techniques is the ability
to preserve the extracellular matrix, thus allowing ablation
adjacent to critical structures as nerves, vessels and biliary
ducts; IRE is therefore the safest ablative approach for tu-
mours encasing major peripancreatic vessels [33]. Irrevers-
ible electroporation has been proposed for palliation of
unresectable tumours of the pancreas, as a bridge therapy
before surgery, and also as a technique for intraoperative
“margin augmentation”, in order to reach R0 resection in
technically unresectable pancreatic tumours [34]. Open,
laparoscopic and percutaneous approaches have been
Fig. 2 Computed tomography of an unresectable pancreatic ductal adenocarcinoma before (a) and after radiofrequency ablation (b). Patient presented with a
locally advanced pancreatic ductal adenocarcinoma (40 × 35mm) involving the celiac trunk. After twelve cycles of FOLFIRINOX chemotherapy, RFA of the
lesion was performed. After the procedure (b), a homogeneous well-demarcated hypodense necrotic area confirmed the success of the procedure. No
complications were reported. c Radiofrequency ablation of a ductal adenocarcinoma (patient setting). The procedure is performed in absolute sterility, in a
surgery room with anaesthesia support. The ablation needle is mounted on a specific support for the probe. The procedure is performed by a single
skilled operator. d Radiofrequency ablation of a ductal adenocarcinoma under ultrasound guidance. Gas bubbles generated during the procedure
spreads centrifugally from the tip of the needle, permitting to monitor the margins of the ablated area in relation to the tumour borders
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evaluated for IRE. In most cases, percutaneous IRE was
performed under CT guidance, with encouraging results in
terms of feasibility, safety and effectiveness [35, 36]. Prelim-
inary studies [37, 38] reported successful percutaneous
US-guided IRE of pancreatic cancer, without significant
procedure-related complications. Månsson et al. [39] re-
ported a median survival of sevenmonths after percutan-
eous US-guided IRE of pancreatic cancer; the median time
from IRE was 6.1months to local progression and 2.7
months to observation of metastases. With larger studies,
data on safety and overall survival after percutaneous
US-guided IRE could be obtained to confirm its long-term
efficacy within a multidisciplinary approach to unresectable
pancreatic cancer.
Cryoablation is increasingly used for the ablation of
unresectable pancreatic cancer. This technique produces
a rapid freezing of the lesion down to temperatures be-
tween −80° and −160 °C by using a cryoprobe. The bio-
logical mechanisms underlying cryoablation are still not
fully understood; nevertheless, it is known that this tech-
nique leads to the destruction of cell membranes and
tissues’ ultrastructure, leading to delayed cell necrosis
and apoptosis [40]. Ultrasound can be used to guide per-
cutaneous cryoablation, but posterior acoustic shadow-
ing limits visualisation, while at CT the frozen lesion
appears as a hypodense “ice ball”. For these reasons, CT
guidance is more frequently adopted to guide percutan-
eous cryoablation. Nevertheless, there have been reports
on successful US-guided percutaneous cryoablation for
pancreatic cancer. Niu et al. [41] reported effective pain
relief after cryoablation, with a ≥ 50% reduction in pain
score in 84% of patients, a 50% decrease in analgesic
consumption in 69% of patients and a ≥ 20 increase in
Karnofsky Performance Status score in 50% of patients.
Xu et al. [42] reported complete tumour response in
20.4% patients, partial response in 38.8%, and stable dis-
ease in 30.6% after percutaneous cryosurgery associated
with 125-iodine seed implantation.
High-intensity focused ultrasound is a non-invasive ab-
lation technique that delivers high-intensity ultrasounds
in a definite area in order to produce both thermal and
mechanical damage. The target region is heated up to
60–80 °C inducing protein denaturation and tissue ne-
crosis [43]. Both US and MR imaging can be used to
guide the procedure; while MR imaging is the most
commonly used technique, US has the advantage to
identify and displace the bowels in order to improve the
effectiveness of the procedure and reduce complications.
HIFU has been proven to be an effective treatment for
patient with advanced pancreatic cancer, by reducing
pain in more than 80% of the cases [44–46]. Marinova
et al. [47] reported that US-guided HIFU induced signifi-
cant early relief of cancer-induced abdominal pain in
84% of patients, with a tumour volume reduction of
37.8 ± 18.1% after 6 weeks and 57.9 ± 25.9% six months
after treatment. The median overall survival and
progression-free survival were 8.3 and 6.8 months from
intervention.
One of the most interesting as well as unknown side of
ablative techniques is the possible role in immunogenic
stimulation. It seems that tumour debris left in situ after
ablation can induce a systemic immune response against
tumour cells, affecting both eventual residual disease and
metastases [48]. In particular, non-thermal techniques as
well as cavitation phenomenon induced by HIFU, not pro-
viding thermal denaturation of tumour antigen, could
stimulate strong cytokines production and a T-cell-medi-
ated reaction against tumour cells [48]. Further studies are
needed in this field.
Novel US techniques for the guidance of
interventional procedures
One of the greatest advances in US imaging has been
the introduction of contrast media. Contrast-enhanced
US (CEUS) is the only imaging technique that allows a
real-time observation of the vascular network, owing to
some particular features: the high-contrast and spatial
resolution, the use of a blood-pool contrast medium and
the real-time dynamic evaluation of tumour enhance-
ment, filtering the background tissue signals [49].
The latest guidelines by the EFSUMB [50] provided the
following recommendations for the use of CEUS prior or
during US-guided pancreatic intervention: distinction be-
tween cystic neoplasms and pseudocysts; differentiation of
vascular (solid) from avascular (e.g. liquid or necrotic)
components of a pancreatic lesion; definition of dimen-
sions and margins of a pancreatic lesion and its vascular
components; diagnosis and follow-up of acute necrotising
pancreatitis; improvement of the accuracy of percutaneous
US-guided pancreatic procedures.
Previous studies reported that CEUS is superior to
Doppler US for both the visualisation of intrapancreatic
vessels and the relationship of pancreatic lesions with
peripancreatic vessels [51]; thus, it can be helpful for
percutaneous intervention in order to better evaluate the
target lesion and to set up the most appropriate pathway
of the biopsy needle. CEUS-guided biopsy may be help-
ful for pancreatic lesions that are barely visible on
B-mode US, thus improving accuracy [52]. Moreover, by
directing the biopsy needle towards solid, enhancing
portions of the lesion, necrotic portions can be avoided,
thus reducing the need for biopsy repetition [50]. As
demonstrated by Mauri et al. [53] for liver lesions, intra-
procedural CEUS could also be useful to instantly assess
the success of pancreatic RFA, detecting incomplete ab-
lations and then reducing the number of retreatments
and overall costs.
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Multimodality fusion imaging is a new technique that
allows a real-time fusion of B-mode US imaging with pre-
viously acquired cross-sectional images, including CT,
MRI, and positron emission tomography - CT (PET-CT)
[54, 55]. This technique has a great potential for interven-
tional radiology, since it associates the characteristics of
two different types of imaging in a single examination,
thus increasing the amount of anatomical, functional and
metabolic information during US-guided procedures.
Fusion imaging is usually used to assist percutaneous
procedures for challenging lesions, especially those char-
acterised by low conspicuity on B-mode US [56]; most
previous experiences on multimodal fusion imaging
(MMFI) were applied to hepatic and prostatic interven-
tion. Theoretically, the pancreas could benefit from this
technique, since being a retroperitoneal organ it is
poorly affected by respiratory movements that could im-
pair real-time image fusion and synchronisation of the
images. Nevertheless, there are very few literature re-
ports on the use of MMFI techniques for US-guided
percutaneous intervention in pancreatic diseases. Sofuni
et al. [57] and Sumi et al. [58] reported potential useful-
ness of fusion imaging for the evaluation of the pancre-
atic tail, a well-known “blind area” for transabdominal
US, and for pancreatic lesions with low conspicuity on
B-mode US. Zhang et al. [59] compared the efficacy of
US guidance alone and US/CT image fusion guidance in
percutaneous drainage of infected walled-off necrosis
following acute pancreatitis. The US/CT fusion group
achieved a significantly higher imaging effective rate,
and significantly lower inflammatory response indexes
and severity score, than the US group; the US/CT fusion
group required fewer puncture times and drainage tubes
and lower rate of advanced treatment, showing higher
operational success rate than the US group. Moreover,
the US/CT fusion group exhibited significantly lower
complications and hospital stay than the US group.
A possible limitation of fusion imaging, when applied
to percutaneous pancreatic intervention, resides in the
necessary compression with the US probe on the
abdomen, which could create discrepancies between
real-time US and previously acquired images (Fig. 3), in
which no compression is applied.
Conclusion
Ultrasound-guided percutaneous intervention for pan-
creatic diseases is increasingly used and is now part of
clinical practice in high-volume centres all over the
world. Technical advances allowed to develop and refine
both diagnostic and therapeutic procedures. The use of
CEUS and fusion imaging allows to increase the accur-
acy, safety, and feasibility of US-guided percutaneous
procedures, reducing time and costs. Ablative techniques
are increasingly used and may represent a therapeutic
treatment within the multidisciplinary approach to pan-
creatic cancer.
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Fig. 3 Ultrasound (US) image fused with a previously acquired computed tomography (CT). Target lesion easily is identified and marked (⊕) on
both sides. Color Doppler confirms the major vessels’ relationship of the lesion well visualised on the CT on the left. Path of the needle precisely
planned (dotted line). Interposed colon on the CT image is displaced on US by the strong compression applied by the probe
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